P707 Anti-TNFα therapy has no effect on bone mineral density in younger patients with inflammatory bowel disease: A single-centre observational study

• Published in: Journal of Crohn's and colitis Vol. 14; no. Supplement_1; p. S572
• Main Authors: Filip, R, Jarmakiewicz - Czaja, S, Piątek, D, Sztembis, J, Pękala, A, Guz, W
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 15.01.2020
• ISSN: 1873-9946; 1876-4479
• DOI: 10.1093/ecco-jcc/jjz203.835

Abstract Background Active inflammation negatively affects bone mineral density. Biological treatment, among others silences the excessive reaction of the immune system, which can also reduce the risk of osteoporosis. The aim of the study is to determine whether bone mineral density is higher in patients with biological therapy. Methods In total, 112 patients over 18 years of age with CD (Crohn’s Disease) or UC (Ulcerative colitis) were included in the study. The mean value age was 35 years. Patients who had received anti-TNFα therapy (biosimilar infliximab CT-P13 or adalimumab), and who underwent densitometric evaluation after two year treatment, were selected. Those who had never received anti-TNFα therapy were selected as controls. Information regarding age, sex, weight, duration of CD, use of glucocorticoids and bisphosphonates, and signs of disease activity at the time of densitometric measurement were collected. Bone mineral density was measured by dual-energy X-ray absorptiometry (DEXA) within femoral neck and lumbar spine. Results are reported as g/cm2 and presented either as Z-score or as a T-score. Results The study group has characterised a mean value BMI (Body Mass Index)—24. The group of patients with anti-TNFαα therapy showed an average T-score left femur −0.7744 (CD) and −0.4382 (UC), but without anti-TNFα therapy −0.6636 (CD) and −0.2208 (UC). The entire study group showed a mean value t-score left femur of −0.54286. There were no significant statistical differences between the examined groups and the effect of anti-TNFα therapy on BMI, T-score left femur, T-score L2–L4 Studied factor Average Median Standard deviation Lower quartile Upper quartile Statistical analysis Crohn’s disease (CD) Anti-TNFα therapy BMI 23.1372 21.7000 3.67281 20.1000 26.6000 p > 0.05 L2–L4 T-score −0.4953 −0.6000 1.36468 −1.5000 0.7000 Left femur T-score −0.7744 −0.8000 1.03420 −1.8000 −0.1000 No anti-TNFα therapy BMI 23.6545 24.0000 3.56549 20.5000 26.6000 p > 0.05 L2–L4 T -score −0.3273 −0.6000 1.33423 −1.1000 0.8000 Left femur T-score −0.6636 −0.8000 0.79909 −1.1000 −0.3000 Colitis ulcerosa (UC) Anti-TNFα therapy BMI 26.0206 23.9500 11.27138 20.5000 28.2000 p > 0.05 L2-L4 T -score −0.1529 −0.2000 1.30853 −1.0000 0.7000 Left femur T - score −0.4382 −0.4000 1.06002 −1.2000 0.0000 No anti-TNFα therapy BMI 23.8833 22.7500 4.83912 20.5000 27.9000 p > 0.05 L2-L4 T-score 0.0833 0.0000 1.27541 −0.6500 1.0500 Left femur T-score −0.2208 −0.2500 0.83613 −0.8000 0.2000 Conclusion The results of the preliminary study assessing the effect of anti-TNFα therapy on bone mineral density among the two treatment groups (CD and UC) do not indicate significant differences after the introduction of such therapy